Syndax Pharmaceuticals Inc current report, 26 March 2019

Vollständiges Dokument

Business Context and Reporting Period

Company: Syndax Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 26, 2019
Event: The Company entered into securities purchase agreements to raise capital through the issuance of common stock, pre-funded warrants, and series warrants.

Key Financial Metrics

Capital Raised: Approximately $27.6 million in aggregate gross proceeds.
Offering Price: $6.00 per share (or $5.9999 for Pre-Funded Warrants).
Securities Issued:

  • 1,866,666 shares of Common Stock (March 26).
  • 228,373 shares of Common Stock (March 28).
  • Pre-Funded Warrants to purchase 2,500,000 shares of Common Stock.
  • Series Warrants (Series 1 and Series 2) to purchase an aggregate of 4,366,666 shares of Common Stock.
Debt and Liquidity: The filing does not provide specific data on existing debt, cash flow, or liquidity positions outside of the proceeds from this offering.

Material Changes and Transaction Terms

The primary material change is the dilution of existing shareholders and the increase in cash reserves resulting from the private placement. Key terms include:

  • Warrant Exercise Prices: Series 1 Warrants at $12.00 per share; Series 2 Warrants at $18.00 per share.
  • Warrant Expiration: The earlier of 90 days following the release of positive overall survival data in the E2112 breast cancer clinical trial, or December 31, 2020.
  • Price Reset Mechanism: If the Company sells equity below $12.00 per share prior to expiration, the Series Warrant exercise price may reset to the midpoint between the initial price and the new weighted-average price, with a floor of $6.00 per share.
  • Pre-Funded Warrants: Exercisable immediately at $0.0001 per share with a 20-year term, allowing investors to defer beneficial ownership.

Guidance, Outlook, and Risks

Management Commentary: The offering was structured to provide immediate capital while aligning investor incentives with the clinical milestone of the E2112 trial. No underwriters or placement agents participated.
Risks and Contingencies:

  • Dilution Risk: Significant potential dilution exists if Pre-Funded Warrants and Series Warrants are exercised.
  • Price Reset Risk: Future equity offerings below $12.00 could trigger a downward adjustment of the Series Warrant exercise price.
  • Clinical Dependency: The expiration of Series Warrants is contingent on the timing of positive clinical data release.
Unusual Items: The filing does not disclose unusual items outside of the specific terms of the warrant reset mechanism.

Investor Verification Checklist

  • Verify the exact number of shares outstanding post-issuance to assess immediate dilution.
  • Confirm the current status and timeline of the E2112 clinical trial to understand the potential expiration date of the Series Warrants.
  • Review the Company's cash burn rate to determine how long the $27.6 million in proceeds will sustain operations.
  • Monitor future equity offerings to see if the $12.00 threshold is breached, which would trigger the warrant price reset.
  • Check the Company's balance sheet for any existing debt covenants that might be affected by this equity issuance.